FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892370306> ?p ?o ?g. }

• W2892370306 endingPage "3315" @default.
• W2892370306 startingPage "3305" @default.
• W2892370306 abstract "The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies Chai Hong Rim,1 Chul Yong Kim,2 Dae Sik Yang,3 Won Sup Yoon1 1Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Ansan, Gyeonggi-do, Republic of Korea; 2Department of Radiation Oncology, Anam Hospital, Korea University Medical College, Seoul, Republic of Korea; 3Department of Radiation Oncology, Guro Hospital, Korea University Medical College, Seoul, Republic of Korea Purpose: Lymph node metastasis of hepatocellular carcinoma is categorized as advanced in Barcelona Clinic of Liver Cancer staging, and sorafenib is a sole treatment recommended. However, appliance of local treatment including external beam radiotherapy (EBRT) has not been uncommon. We performed a meta-analysis and systemically reviewed current literature to evaluate the efficacy and safety of EBRT. Methods: PubMed, Medline, Cochrane library, and Embase were systemically searched until December 17, 2017. The primary endpoint of analyses was response rate (RR), and 1-year overall survival and complication rates of grade ≥3 were secondary endpoints. Complications were primarily assessed descriptively. Results: A total of 8 studies comprising 521 patients were included. The pooled RR was 73.1% (95% confidence interval [CI]: 63.6–80.9), and high-dose EBRT groups had better RR than the low-dose group (82.2% [95% CI: 74.4–88.1] vs 51.1% [95% CI: 40.3–61.7]; P=0.001]. The pooled 1-year overall survival rate was 41.0% (95% CI: 32.9–49.6). Six studies assessed the survival benefit according to RR, and 5 (83.3%) of these 6 studies reported statistically significant survival benefit. The most common grade ≥3 toxicities were thrombocytopenia and gastrointestinal complication, with pooled rates of 3.4% (95% CI: 1.2–9.5) and 3.5% (95% CI:1.7–7.2), respectively. Conclusion: EBRT showed a pooled RR of 73.1% and was safely performed. EBRT might palliate symptoms through tumor reductions and improve survival. Use of sorafenib combined or sequentially with EBRT can be recommended rather than monotherapy. Keywords: hepatocellular carcinoma, lymph node metastasis, meta-analysis, radiation therapy" @default.
• W2892370306 created "2018-09-27" @default.
• W2892370306 creator A5045234344 @default.
• W2892370306 creator A5045567806 @default.
• W2892370306 creator A5070298796 @default.
• W2892370306 creator A5085999785 @default.
• W2892370306 date "2018-09-01" @default.
• W2892370306 modified "2023-10-01" @default.
• W2892370306 title "The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies" @default.
• W2892370306 cites W1195984504 @default.
• W2892370306 cites W1967046314 @default.
• W2892370306 cites W1971837077 @default.
• W2892370306 cites W1974741599 @default.
• W2892370306 cites W1979423827 @default.
• W2892370306 cites W1980329348 @default.
• W2892370306 cites W1982068113 @default.
• W2892370306 cites W1986533360 @default.
• W2892370306 cites W1990823682 @default.
• W2892370306 cites W1994193851 @default.
• W2892370306 cites W2019607817 @default.
• W2892370306 cites W2020943077 @default.
• W2892370306 cites W2039630064 @default.
• W2892370306 cites W2065267852 @default.
• W2892370306 cites W2069486732 @default.
• W2892370306 cites W2085514795 @default.
• W2892370306 cites W2087339853 @default.
• W2892370306 cites W2090028057 @default.
• W2892370306 cites W2090874796 @default.
• W2892370306 cites W2119617388 @default.
• W2892370306 cites W2142268852 @default.
• W2892370306 cites W2147959998 @default.
• W2892370306 cites W2150206931 @default.
• W2892370306 cites W2151684674 @default.
• W2892370306 cites W2154204813 @default.
• W2892370306 cites W2157823046 @default.
• W2892370306 cites W2319192473 @default.
• W2892370306 cites W2467518787 @default.
• W2892370306 cites W2526397003 @default.
• W2892370306 cites W2588681363 @default.
• W2892370306 cites W4245784696 @default.
• W2892370306 cites W83217465 @default.
• W2892370306 doi "https://doi.org/10.2147/cmar.s175703" @default.
• W2892370306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6132227" @default.
• W2892370306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30233246" @default.
• W2892370306 hasPublicationYear "2018" @default.
• W2892370306 type Work @default.
• W2892370306 sameAs 2892370306 @default.
• W2892370306 citedByCount "14" @default.
• W2892370306 countsByYear W28923703062019 @default.
• W2892370306 countsByYear W28923703062020 @default.
• W2892370306 countsByYear W28923703062021 @default.
• W2892370306 countsByYear W28923703062022 @default.
• W2892370306 countsByYear W28923703062023 @default.
• W2892370306 crossrefType "journal-article" @default.
• W2892370306 hasAuthorship W2892370306A5045234344 @default.
• W2892370306 hasAuthorship W2892370306A5045567806 @default.
• W2892370306 hasAuthorship W2892370306A5070298796 @default.
• W2892370306 hasAuthorship W2892370306A5085999785 @default.
• W2892370306 hasBestOaLocation W28923703061 @default.
• W2892370306 hasConcept C126322002 @default.
• W2892370306 hasConcept C143998085 @default.
• W2892370306 hasConcept C203092338 @default.
• W2892370306 hasConcept C23131810 @default.
• W2892370306 hasConcept C2775908122 @default.
• W2892370306 hasConcept C2776478404 @default.
• W2892370306 hasConcept C2777416452 @default.
• W2892370306 hasConcept C2778019345 @default.
• W2892370306 hasConcept C2778695046 @default.
• W2892370306 hasConcept C509974204 @default.
• W2892370306 hasConcept C535046627 @default.
• W2892370306 hasConcept C71924100 @default.
• W2892370306 hasConcept C95190672 @default.
• W2892370306 hasConceptScore W2892370306C126322002 @default.
• W2892370306 hasConceptScore W2892370306C143998085 @default.
• W2892370306 hasConceptScore W2892370306C203092338 @default.
• W2892370306 hasConceptScore W2892370306C23131810 @default.
• W2892370306 hasConceptScore W2892370306C2775908122 @default.
• W2892370306 hasConceptScore W2892370306C2776478404 @default.
• W2892370306 hasConceptScore W2892370306C2777416452 @default.
• W2892370306 hasConceptScore W2892370306C2778019345 @default.
• W2892370306 hasConceptScore W2892370306C2778695046 @default.
• W2892370306 hasConceptScore W2892370306C509974204 @default.
• W2892370306 hasConceptScore W2892370306C535046627 @default.
• W2892370306 hasConceptScore W2892370306C71924100 @default.
• W2892370306 hasConceptScore W2892370306C95190672 @default.
• W2892370306 hasLocation W28923703061 @default.
• W2892370306 hasLocation W28923703062 @default.
• W2892370306 hasLocation W28923703063 @default.
• W2892370306 hasLocation W28923703064 @default.
• W2892370306 hasLocation W28923703065 @default.
• W2892370306 hasLocation W28923703066 @default.
• W2892370306 hasOpenAccess W2892370306 @default.
• W2892370306 hasPrimaryLocation W28923703061 @default.
• W2892370306 hasRelatedWork W2041803801 @default.
• W2892370306 hasRelatedWork W2363148386 @default.
• W2892370306 hasRelatedWork W2539252963 @default.
• W2892370306 hasRelatedWork W2791082369 @default.
• W2892370306 hasRelatedWork W2794122361 @default.

• next